PCI Biotech Holding ASA (OSL:PCIB)
Norway
· Delayed Price · Currency is NOK 1.500
+0.040 (2.67%)
Apr 28, 2025, 9:29 AM CET
PCI Biotech Holding ASA Revenue
In the year 2024, PCI Biotech Holding ASA had annual revenue of 6.74M NOK with 125.25% growth. PCI Biotech Holding ASA had revenue of 3.31M in the half year ending December 31, 2024, with 39.33% growth.
Revenue
6.74M
Revenue Growth
+125.25%
P/S Ratio
8.31
Revenue / Employee
1.12M
Employees
6
Market Cap
55.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.74M | 3.75M | 125.25% |
| Dec 31, 2023 | 2.99M | -1.76M | -37.05% |
| Dec 31, 2022 | 4.75M | -1.52M | -24.28% |
| Dec 31, 2021 | 6.27M | -1.10M | -14.86% |
| Dec 31, 2020 | 7.37M | -2.02M | -21.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 556.16M |
| Nordhealth AS | 537.23M |
| Photocure ASA | 525.39M |
| Vistin Pharma ASA | 429.50M |
| ArcticZymes Technologies ASA | 108.11M |
| Omda AS | 426.27M |
| Nykode Therapeutics AS | 104.04M |
| Gentian Diagnostics ASA | 152.07M |